Register or Sign in to Save this opportunity, or Send an Inquiry.
PCSK9- Single Domain Antibody Inhibitor
AmorChem Canada flag Canada
Abstract ID:
We have identified a number of single domain antibodies (sdAbs) which bind PCSK9. sdAbs provide an interesting novel modality to bind this target and are more cost effective than mAbs to manufacture.
Send an Inquiry

Hyperlipidemia is a predominant risk factor for cardiovascular disease (CVD). Mutation in low-density lipoprotein receptor ( LDLR) or apolipoprotein B (ApoB) genes are major causes of familial hypercholesterolemia. Proprotein convertase subtilisin/kexin type 9 (PCSK9) was a third gene involved in this familial disease and plays an important role in the metabolism of low-density lipoprotein cholesterol (LDL-c). PCSK9 degrades the LDL-receptor, improves the lipoprotein profile and future cardiovascular outcomes in patients with dyslipidemia.

Recent Phase 2 clinical data (Amgen) obtained using antibodies to block its action show up to 60% reduction in levels of LDL-c. However, there are no single domain antibodies under development for this target. We believe this product could position itself quite competitively in the biological landscape; providing the specificity of monoclonal antibodies but at the fraction of the price.

Type of Business Relationship Sought
Out-licensing or collaboration
Last Updated Jul 2017
Technology Type PLATFORM
Phase of Development EARLY STAGE

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833